TABLE 3.
Joint effects of MTHFR polymorphism and riboflavin status on CIN 2 or 3 among 435 women with high-risk human papilloma virus.
| MTHFR / RIBOFLAVIN STATUS | Odds Ratio1, 95% CI, p value | Odds Ratio2, 95% CI, p value |
|---|---|---|
| Any polymorphism /Low: > Median EGRAC (> 1.4)
Any polymorphism /High: ≤ Median EGRAC (≤1.4) No polymorphism /Low: > Median EGRAC (> 1.4) No polymorphism /High: ≤ Median EGRAC (≤ 1.4) |
0.31, 0.12–0.80, 0.016
0.54, 0.24–1.20, 0.129 1.46, 0.81–2.63, 0.211 1 (Reference) |
0.35, 0.13–0.92, 0.034
0.51, 0.22–1.19, 0.119 1.62, 0.89–2.97, 0.117 1 (Reference) |
| Any polymorphism /Low (> 1.5 EGRAC)
Any polymorphism / Medium (>1.3–1.5 EGRAC) Any polymorphism / High (≤ 1.3 EGRAC) No polymorphism / Low (> 1.5 EGRAC) No polymorphism /Medium (>1.3–1.5 EGRAC) No polymorphism /High (≤ 1.3 EGRAC) |
0.20, 0.06–0.74, 0.015
0.45, 0.17–1.18, 0.106 0.45, 0.17–1.21, 0.114 1.07, 0.51–2.26, 0.856 1.02, 0.51–2.05, 0.943 1 (Reference) |
0.22, 0.06–0.82, 0.024
0.47, 0.18–1.25, 0.132 0.37, 0.12–1.12, 0.078 1.16, 0.54–2.46, 0.708 1.00, 0.49–2.02, 0.998 1 (Reference) |
1
OR adjusted for age, race, smoking (ever/never), age at first intercourse, use of hormonal contraception (yes/no), and study arm
2
OR adjusted for age, race, smoking (ever/never), age at first intercourse, use of hormonal contraception (yes/no), study arm, and micronutrient concentrations of plasma folate, vitamins B-12, C, A, E and total carotene.